Amneal Gains Approval for Erythromycin Tablets, USP

March 14, 2018

Bridgewater, NJ (USA), March 14, 2018 – Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets of Arbor Pharmaceuticals and is the only other immediate release oral tablet available.

“Amneal is committed to increasing access to affordable medications,” said Amneal EVP-Commercial Operations Andy Boyer. “Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”

Amneal’s erythromycin tablets are sold in 100-count bottles and are now available for shipping to wholesalers, distributors and direct to the trade.

Annual U.S. sales of erythromycin tablets were $84 million, according to January 2018 IQVIA™ market data.